Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the Beck Depression Inventory

Journal of Urban Health

Volumn 81, Issue 2, 2004, Pages 278-290

  Golub, Elizabeth T ^a   Latka, Mary ^b   Hagan, Holly ^c   Havens, Jennifer R ^a   Hudson, Sharon M ^d   Kapadia, Farzana ^b   Campbell, Jennifer V ^e   Garfein, Richard S ^f   Thomas, David L ^g   Strathdee, Steffanie A ^a,h  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NEW YORK ACADEMY OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Health Research Association   (United States)

^e PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Beck Depression Inventory (BDI); Center for Epidemiologic Studies Depression Scale (CES D); Depression; Hepatitis C infection; Injection drug users (IDUs); Interferon

Indexed keywords

INTERFERON;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DEPRESSION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING; SYMPTOMATOLOGY; TREATMENT OUTCOME; VIRUS TRANSMISSION;

ADOLESCENT; COHORT STUDIES; DEPRESSIVE DISORDER, MAJOR; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEPATITIS C; HUMANS; MALE; PERSONALITY INVENTORY; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES; URBAN HEALTH; URBAN POPULATION;

EID: 1842620533     PISSN: 10993460     EISSN: None     Source Type: Journal    
DOI: 10.1093/jurban/jth114     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Viral Hepatitis and Injection Drug Users. 2002. Available at: www.cdc.gov/idu.
2. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA. 2000;284:450-456.
3. Management of Hepatitis C: 2002. NIH Consens State Sci Statements. 2002 Jun 10-12; 19(3):1-41.
4. Edlin BR, Seal KH, Lorvick J, et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med. 2001;345:211-215.
5. Management of Hepatitis C. NIH Consensus Statement 1997 Mar 24-26;15(3):1-41.
6. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7:942-947.
7. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72:237-241.
8. Khantizian EJ, Treece C. DSM-III psychiatric diagnoses of narcotic addicts. Arch Gen Psychiatry. 1985;42:1067-1071.
9. Ross HE, Glaser FB, Germanson F. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry. 1988;45:1023-1031.
10. Rounsaville BJ, Weissman MM, Kleber HD, et al. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry. 1982;39:161-166.
11. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. Am J Gastroenterol. 1998;93:785-789.
12. Knowlton AR, Latkin CA, Schroeder JR, Hoover DR, Ensminger M, Celentano DD. Longitudinal predictors of depressive symptoms among low income injection drug users. AIDS Care. 2001;13:549-559.
13. Dinwiddie SH, Reich T, Cloninger CR. Psychiatric comorbidity and suicidality among intravenous drug users. J Clin Psychiatry. 1992;53:364-369.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington, DC: American Psychiatric Association; 1994.
15. Brienza RS, Stein MD, Chen M, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat. 2000;18:331-337.
16. Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I. Depression severity and drug injection HIV risk behaviors. Am J Psychiatry. 2003;160:1659-1662.
17. Swartz MS, Swanson JW, Hannon MJ, et al. Blood-borne infections and persons with mental illness: regular sources of medical care among persons with severe mental illness at risk of hepatitis C infection. Psychiatr Serv. 2003;54:854-859.
18. Scalori A, Apale P, Panizzuti F, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol. 2000;12:505-509.
19. Macalino GE, Celentano DD, Latkin C, Strathdee SA, Vlahov D. Risk behaviors by audio computer-assisted self-interviews among HIV-seropositive and HIV-seronegative injection drug users. AIDS Educ Prev. 2002;14:367-378.
20. Newman JC, Des J, Turner CF, Gribble J, Cooley P, Paone D. The differential effects of face-to-face and computer interview modes. Am J Public Health. 2002;92:294-297.
21. Metzger DS, Koblin B, Turner C, et al. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am J Epidemiol. 2000;152:99-106.
22. Centers for Disease Control and Prevention. HIV counseling, testing and referral standards and guidelines. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1994.
23. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Measure. 1977;1:385-401.
24. Clark CH, Mahoney JS, Clark DJ, Eriksen LR. Screening for depression in a hepatitis C population: the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs. 2002;40:361-369.
25. Roberts RE. Reliability of the CES-D scale in different ethnic contexts. Psychiatry Res. 1980;2:125-134.
26. Weissman MW, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ. Assessing depressive symptoms in five psychiatric populations, a validation study. Am J Epidemiol. 1977;106:203-214.
27. Perdue T, Hagan H, Thiede H, Valleroy L. Depression and HIV risk behavior among Seattle-area injection drug users and young men who have sex with men. AIDS Educ Prev. 2003;15:81-92.
28. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
29. Joe GW, Knezek L, Watson D, Simpson DD. Depression and decision-making among intravenous drug users. Psychol Rep. 1991;68:339-347.
30. Beck AT, Steer RA, Garbin MG. Psychometric properties of the Beck Depression Inventory: 25 years of evaluation. Clin Psychol Rev. 1988;8:77-100.
31. Shaw BF, Steer RA, Beck AT, Schut J. The structure of depression in heroin addicts. Br J Addict Alcohol Other Drugs. 1979;74:295-303.
32. Reynolds WM, Gould JW. A psychometric investigation of the standard and short form Beck Depression Inventory. J Consult Clin Psychol. 1981;49:306-307.
33. Mulder RT, Ang M, Chapman B, Ross A, Stevens IF, Edgar C. Interferon treatment is not associated with a worsening of psychiatric symptoms in patients with hepatitis C. J Gastroenterol Hepatol. 2000;15:300-303.
34. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.
35. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63:194-198.
36. Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002;35:704-8.
37. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology. 2003;37:443-451.